Mineralys Therapeutics, Inc. MLYS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s total current liabilities?
- Mineralys Therapeutics, Inc. (MLYS) reported total current liabilities of $14.72M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Mineralys Therapeutics, Inc.'s total current liabilities increased by 10.0% year-over-year, from $13.39M to $14.72M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s total current liabilities?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s total current liabilities has grown at a 23.3% compound annual growth rate (CAGR), from $8.07M to $15.11M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.